Discovery calls for Series B companies: scaling without breaking for healthcare and life sciences in the Middle East

This edition of the Growth Broker playbook is written for commercial leaders at healthtech, medtech, and life-sciences companies operating in the Middle East. In this market, Middle Eastern buyers reward in-person credibility, sovereign fit, and patient sequencing, so the way you install discovery calls has to be shaped to that reality from day one.

Series B is the stress test for discovery calls. What worked at fifteen people fails at fifty unless the operating rhythm is deliberate.

The Series B move is to separate the model owner from the operators. One senior human owns strategy, discovery-to-opportunity conversion, and the weekly review; a small team runs the machine.

Add a second geography or segment only when the first one is producing a defensible number for two full quarters. Not before.

Inside healthcare and life sciences, the binding constraint is almost always regulated-sale cycle length, not intent, and in the Middle East it is compounded by the fact that senior-relationship access, not product is what actually gates growth. Discovery calls is only useful here when it is pointed at both constraints at once.

Governance appears at Series B — that is fine, provided it accelerates rather than slows. The test is whether reviews still make decisions or just distribute updates.

The Series B failure mode of discovery calls is reading a script instead of running a diagnosis, amplified by headcount. Fix the root cause; do not paper over it with more people.

Compensation begins to matter now. Pay operators on discovery-to-opportunity conversion outcomes, not on effort. Effort-based comp at Series B produces theatre.

A well-run discovery calls function at Series B is the moat that survives to Series C. Companies that skip this discipline burn through raises trying to buy it back.

Concretely for healthcare and life sciences in the Middle East: the healthcare teams that install this get past procurement instead of dying in it, and one sovereign or family-office win in the Middle East justifies a full year of program spend. That is the reason it is worth installing discovery calls deliberately for this market rather than importing a playbook designed for somewhere else.